{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Catellani C"],"pubmed_abstract":["Introduction
Giant Cell Arteritis (GCA) is the most common vasculitis in the elderly, characterized by granulomatous infiltration of immune cells in medium and large arteries. A therapeutic protocol that combines ultra-short glucocorticoids (GC) followed by tocilizumab (TCZ) monotherapy has been proven effective in GCA patients with extracranial large vessel involvement (LV-GCA). However, its effects on circulating immune cells are unknown. The aim of this study was to deepen the understanding of the immunological mechanisms behind this treatment regimen in patients with LV-GCA.Methods
15 patients with active LV-GCA were included in this study. Blood samples were collected at baseline, after 3 days of GC treatment, at weeks 24 and 52 during TCZ monotherapy, and at week 78 a"],"journal":["Frontiers in immunology"],"pagination":["1516008"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11983418"],"repository":["biostudies-literature"],"pubmed_title":["Glucocorticoid boluses followed by tocilizumab in giant cell arteritis patients: effects on peripheral blood monocytes and lymphocytes."],"pmcid":["PMC11983418"],"pubmed_authors":["Buia V","Casali M","Salvarani C","Catanoso M","Zerbini A","Muratore F","Ferrigno I","Versari A","Besutti G","Bonacini M","Marvisi C","Croci S","Catellani C","Boiardi L","Spaggiari L","Di Tommaso G","Cassone G","Durmo R","Rossi A"],"additional_accession":[]},"is_claimable":false,"name":"Glucocorticoid boluses followed by tocilizumab in giant cell arteritis patients: effects on peripheral blood monocytes and lymphocytes.","description":"Introduction
Giant Cell Arteritis (GCA) is the most common vasculitis in the elderly, characterized by granulomatous infiltration of immune cells in medium and large arteries. A therapeutic protocol that combines ultra-short glucocorticoids (GC) followed by tocilizumab (TCZ) monotherapy has been proven effective in GCA patients with extracranial large vessel involvement (LV-GCA). However, its effects on circulating immune cells are unknown. The aim of this study was to deepen the understanding of the immunological mechanisms behind this treatment regimen in patients with LV-GCA.Methods
15 patients with active LV-GCA were included in this study. Blood samples were collected at baseline, after 3 days of GC treatment, at weeks 24 and 52 during TCZ monotherapy, and at week 78 a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-01T11:06:38.567Z","creation":"2025-07-07T03:10:11.048Z"},"accession":"S-EPMC11983418","cross_references":{"pubmed":["40213553"],"doi":["10.3389/fimmu.2025.1516008"]}}